Abstract 1389P
Background
Patients with pre-existing autoimmune disease (PAD) have been largely excluded from clinical trials of immune checkpoint inhibitor (ICI) therapy in lung cancer. Real-world data is needed to explore the tolerability and activity of this drug class in this unique population.
Methods
We performed a retrospective study of patients treated with ICI therapy between 2012 and 2022 at CancerCare Manitoba (Winnipeg, Canada). Pharmacy records were used to determine ICI exposure. A review of the electronic health record was conducted to identify patients with lung cancer and PAD. The PAD group was matched (1:2) to a non-PAD group based on age and sex. The primary outcome of study was immunotoxicity, defined as either a flare of the PAD or a new immune-related adverse event (irAE). Other outcomes included objective response rate (ORR), time to treatment failure (TTF), and overall survival (OS) in the subgroup with advanced disease. Time-to-event outcomes were modeled using Kaplan-Meier analysis. Logistic regression was used to examine the association between PAD status and irAEs.
Results
1891 patients treated with ICI were retrospectively screened for PAD and a diagnosis of lung cancer. We identified 69 patients with PAD, matched to 142 patients without PAD. 66.8% had adenocarcinoma, 25.6% had squamous cell carcinoma, and 2.8% had small cell carcinoma. 49.9% of patients were treated with anti-PD-1 monotherapy. The incidence of immunotoxicity in the PAD group was 55.1% vs. 39.4% in the non-PAD group (p=0.03). The incidence of flare of the underlying PAD was 20.3%. There was no difference in incidence of high-grade irAEs between the PAD vs. non-PAD group (17% vs 24%, p=0.45). Controlling for ICI type, there was no significant association between PAD status and irAE (odds ratio=1.27, 95% CI 0.71-2.27, p=0.43). No significant differences were observed in ORR, TTF and OS in patients with advanced disease.
Conclusions
PAD status was not associated with higher incidence of irAEs in patients with lung cancer treated with ICI therapy. 1 in 5 patients with PAD experienced a flare of the underlying PAD. In those with advanced stage disease, no difference was observed in oncologic outcomes. These results should be confirmed in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CancerCare Manitoba.
Funding
University of Manitoba.
Disclosure
D. Dawe: Financial Interests, Personal, Advisory Board, Compensated for advisory board attendance: AstraZeneca, Merck, Pfizer, Jazz Pharmaceuticals, Roche, Novartis, Johnson & Johnson; Financial Interests, Personal, Other, Creation of educational content: Bristol Myers Squibb; Financial Interests, Institutional, Coordinating PI, Two research grants, totaling $60,000 over the last 5 years: AstraZeneca; Non-Financial Interests, Leadership Role, Chair of the CAMO Fellowship Committee: Canadian Association of Medical Oncologists; Non-Financial Interests, Project Lead, Chair of the Small Cell Lung Cancer Working Group: Canadian Cancer Trials Group. All other authors have declared no conflicts of interest.
Resources from the same session
1393TiP - A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)
Presenter: Nicolas Girard
Session: Poster session 06
1394TiP - KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
Presenter: Marina Garassino
Session: Poster session 06
1395TiP - A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Presenter: Antonio Passaro
Session: Poster session 06
1397TiP - Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Presenter: Stephen Liu
Session: Poster session 06
Resources:
Abstract
1398TiP - Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Presenter: Solange Peters
Session: Poster session 06
1399TiP - Phase III, double-blind study of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer: Protocol of a study (IPElife trial)
Presenter: Danielli Matias
Session: Poster session 06
1728P - Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
Presenter: Sant Chawla
Session: Poster session 06
1729P - Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma
Presenter: Anmol Dia Agarwal
Session: Poster session 06
1730P - Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma
Presenter: NingNing Lu
Session: Poster session 06
Resources:
Abstract